Many non-small cell lung cancers (NSCLC) fail to respond to standard therapies, or they return despite initial (first-line) treatments. Researchers are therefore seeking more effective and better tolerated therapies. The purpose of this study is to assess the effectiveness of an investigational drug called MPDL3280A in patients with locally advanced or metastatic NSCLC.
MPDL3280A is designed to improve the immune system’s ability to recognize and destroy cancer cells by blocking PD-L1, a protein made by some cancers. MPDL3280A is given intravenously (by vein) once every three weeks.
Patients in this study must have NSCLC tumors that express PD-L1. This PD-L1 expression by the tumor is thought to select those patients who are more likely to benefit from MPDL3280A.